Background: Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells.
There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among …

Background Pivotal trials of chimeric antigen receptor T-cell (CAR-T) have identified
common toxicities but may have been underpowered to detect cardiovascular and …

Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of
patients with relapsed and refractory hematologic malignancies and is increasingly …

Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer
therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted …

Background Anti-CD19 chimeric antigen receptor (CAR) T cell therapy holds great promise
in the treatment of patients with hematologic malignancies. A high occurrence of cardiac …

Chimeric antigen receptor (CAR) T cell therapy is approved in the United States for the
treatment of acute lymphocytic leukemia and aggressive B cell lymphomas. Multiple …

For the 116 patients with serial echocardiograms, median LVEF was 60% at baseline and
follow-up. A total of 12 (10.3%) patients developed new (n= 11) or worsening …

Immunotherapy with chimeric antigen receptor (CAR)-modified T cells targeting CD19 for
pediatric acute lymphoblastic leukemia (ALL) has demonstrated significant efficacy. The …

T-cell therapies, such as chimeric antigen receptor (CAR) T-cell, bispecific T-cell engager
(BiTE) and tumor-infiltrating lymphocyte (TIL) therapies, fight cancer cells harboring specific …

Chimeric antigen receptor (CAR) T cells can produce durable remissions in hematologic
malignancies that are not responsive to standard therapies. Yet the use of CAR T cells is …